Trending...
- Tampa-Based Digital Marketing Agency Launches New Website to Help Local Businesses Grow Online
- Global Families Turn to Young Travelers Concierge Amid Rising Safety Concerns in the U.S
- Meditech International Inc. and Los Angeles Rams Continue Strategic Partnership to Enhance Athlete Performance and Recovery
~ At the 2025 American Association for Cancer Research (AACR) Annual Meeting in Chicago, Hyundai Bioscience presented groundbreaking results from their Penetrium™ combination preclinical studies. These studies have challenged the long-standing belief that genetic resistance is the primary cause of treatment failure in cold tumors, instead revealing that pseudo-resistance – a physical barrier caused by stiffened extracellular matrix (ECM) – is the true obstacle.
For decades, the dominant theory behind cancer treatment failure has been focused on genetic mutations. However, Hyundai Bioscience's latest findings have shown that it is actually the stiffened ECM that prevents immune cells and antibodies from reaching the tumor core. This discovery has led to the development of Penetrium™, a therapy that remodels the ECM and restores infiltration pathways, allowing for effective drug and immune cell access.
In preclinical studies using a triple-negative breast cancer (TNBC) mouse model, Penetrium™ combined with anti-PD-1 therapy resulted in a 48.3% reduction in tumor burden compared to anti-PD-1 monotherapy. Additionally, complete elimination of metastasis was observed in the combination group while it remained present in the monotherapy group. Notably, necrosis was induced within just three days of Penetrium™ administration and continued to grow with repeated dosing – a trend not seen in the control group.
More on illi News
In another study using a metastatic lung cancer model, Penetrium™ combined with antibody therapy showed complete suppression of lung metastasis at a dosage of 100 mg/kg. This was significantly more effective than bevacizumab monotherapy which only showed 33% suppression. The study also revealed a decrease in MMP-9 and VEGF expression, confirming ECM normalization and restoration of drug penetration routes at a molecular level.
Furthermore, when combined with chemotherapy, Penetrium™ was able to overcome limitations seen with paclitaxel monotherapy, which paradoxically promoted lung metastasis. The combination of Penetrium™ and paclitaxel resulted in a 70-80% reduction in metastatic lesion areas compared to controls. This was accompanied by a suppression of MMP-9 and restoration of E-cadherin, demonstrating that Penetrium™ not only enhances chemotherapy efficacy but also structurally blocks metastasis without additional toxicity.
These results have also been validated in a naturally occurring canine mammary cancer model, where the combination of Penetrium™ and POLYTAXEL® showed stronger responses in metastatic tumors compared to primary tumors. This challenges the long-standing notion that metastatic cancer is untreatable.
More on illi News
Dr. Soo-Jung Kim, Head of Research at Hyundai Bioscience, stated that Penetrium™ is the world's first platform to structurally solve infiltration failure in cold tumors. She also announced that Hyundai Bioscience will soon initiate clinical trials for both TNBC and metastatic lung cancer using Penetrium™ combinations.
The safety and clinical readiness of Penetrium™ have been established through a Phase 2 COVID-19 trial using the same API, niclosamide. In addition, it has been administered at less than 9% of the NOAEL dose established in a 13-week GLP-compliant toxicity study.
Hyundai Bioscience is currently conducting a Phase 1 trial for prostate cancer in South Korea and preparing for an investigator-initiated trial for acute myeloid leukemia (AML) in France. With its potential applicability to various types of cancers including pancreatic, gallbladder, ovarian cancers, and hematological malignancies such as AML, Penetrium ECM Remodeling Therapy™ is evolving into a tumor-agnostic universal cancer treatment platform.
This groundbreaking research by Hyundai Bioscience has not only provided a solution to infiltration failure in cold tumors but has also proven that metastatic cancers can be effectively treated. This marks a historic achievement in the field of oncology and brings hope for improved cancer treatments in the future.
For decades, the dominant theory behind cancer treatment failure has been focused on genetic mutations. However, Hyundai Bioscience's latest findings have shown that it is actually the stiffened ECM that prevents immune cells and antibodies from reaching the tumor core. This discovery has led to the development of Penetrium™, a therapy that remodels the ECM and restores infiltration pathways, allowing for effective drug and immune cell access.
In preclinical studies using a triple-negative breast cancer (TNBC) mouse model, Penetrium™ combined with anti-PD-1 therapy resulted in a 48.3% reduction in tumor burden compared to anti-PD-1 monotherapy. Additionally, complete elimination of metastasis was observed in the combination group while it remained present in the monotherapy group. Notably, necrosis was induced within just three days of Penetrium™ administration and continued to grow with repeated dosing – a trend not seen in the control group.
More on illi News
- This Budget Didn't Break the System—It Exposed the Truth
- Statement From EWTN Chairman & CEO Michael P. Warsaw On The Election of Pope Leo XIV
- NBA Champion Lamar Odom Launches Anti-Addiction Meme Coin, Ushering in a Disruptive Innovation in Web3
- Mentor Agile Empowers Illinois Residents with Free Access To Product Management Training
- Midwest Pond Features & Landscapes Hits 100 Cleanouts This Spring, Expands Services Across Chicago
In another study using a metastatic lung cancer model, Penetrium™ combined with antibody therapy showed complete suppression of lung metastasis at a dosage of 100 mg/kg. This was significantly more effective than bevacizumab monotherapy which only showed 33% suppression. The study also revealed a decrease in MMP-9 and VEGF expression, confirming ECM normalization and restoration of drug penetration routes at a molecular level.
Furthermore, when combined with chemotherapy, Penetrium™ was able to overcome limitations seen with paclitaxel monotherapy, which paradoxically promoted lung metastasis. The combination of Penetrium™ and paclitaxel resulted in a 70-80% reduction in metastatic lesion areas compared to controls. This was accompanied by a suppression of MMP-9 and restoration of E-cadherin, demonstrating that Penetrium™ not only enhances chemotherapy efficacy but also structurally blocks metastasis without additional toxicity.
These results have also been validated in a naturally occurring canine mammary cancer model, where the combination of Penetrium™ and POLYTAXEL® showed stronger responses in metastatic tumors compared to primary tumors. This challenges the long-standing notion that metastatic cancer is untreatable.
More on illi News
- Aureli Construction Sets the Standard for Seamless Home Additions in Greater Boston
- ScreenPoints Puts Film Investors in the Credits—and in the Money With New FinTech Platform
- Beyond Finance Wins Gold Stevie® Award for Customer Service Department of the Year in 23rd Annual American Business Awards
- Pathways to Adulthood Conference May 17 at Melville Marriott Honoring NYS Assembly Member Jodi Giglio, Suffolk County Legislator Nick Caracappa
- Adster Techologies awarded US Patent for breakthrough innovation in reducing latency in Ad Serving
Dr. Soo-Jung Kim, Head of Research at Hyundai Bioscience, stated that Penetrium™ is the world's first platform to structurally solve infiltration failure in cold tumors. She also announced that Hyundai Bioscience will soon initiate clinical trials for both TNBC and metastatic lung cancer using Penetrium™ combinations.
The safety and clinical readiness of Penetrium™ have been established through a Phase 2 COVID-19 trial using the same API, niclosamide. In addition, it has been administered at less than 9% of the NOAEL dose established in a 13-week GLP-compliant toxicity study.
Hyundai Bioscience is currently conducting a Phase 1 trial for prostate cancer in South Korea and preparing for an investigator-initiated trial for acute myeloid leukemia (AML) in France. With its potential applicability to various types of cancers including pancreatic, gallbladder, ovarian cancers, and hematological malignancies such as AML, Penetrium ECM Remodeling Therapy™ is evolving into a tumor-agnostic universal cancer treatment platform.
This groundbreaking research by Hyundai Bioscience has not only provided a solution to infiltration failure in cold tumors but has also proven that metastatic cancers can be effectively treated. This marks a historic achievement in the field of oncology and brings hope for improved cancer treatments in the future.
Filed Under: Business
0 Comments
Latest on illi News
- $56.7 Million Announced in Q1 2025 with Revenue Growth and Progress Toward NASDAQ Uplisting for AI Marketing Company: IQSTEL, Inc. Stock Symbol: IQSTD
- SAVVY MINING raised $500 million and launched BTC.XRP.DOGE cloud mining, increasing investors' returns by 30%
- New National Nonprofit Launches to Capture Firsthand Accounts of Adoption Stories
- The Tide Project Opens at Biennale Architettura 2025 in Venice Amplifying Youth Voices
- Wall Street analysts say BTC.XRP.DOGE cloud mining company SIX MINING is expected to achieve a 5-fold increase, allowing users to easily mine BTC
- Gen X Takes The Reins: New Book Guides Caregivers Juggling Parents, Kids, And Grandkids With Humor And Heart
- Naperville Welcomes Top Global Leaders Through Americas Competitiveness Exchange Visit
- Fray Fitness Launches Memorial Day Sale and Veteran Organization Giveaway
- ABM for Good™ Launches First Project with Build Change
- Local Nonprofit Files Lawsuit Against Trump Administration's Attack on AmeriCorps
- Pregis Honors Partners Driving Measurable Impact with Annual Pregis Purpose Awards
- ImagineX, in Collaboration with Qualys, Launches New mROC Services to Transform Enterprise Cyber Risk Management
- Ditch Micromanagement: New Leadership Book for Results-Driven, Accountability-Based Teams
- Jay Tapp was named Managing Director in British Columbia
- Hubei Heavy Equipment Makes a Striking Appearance at CIMT and Competes with International Brands
- 20 Patents Issued Worldwide, Cementing Company Leadership. First Ever Cable-Free 12-Lead ECG: HeartBeam, Inc. (Stock Symbol: BEAT)
- NASDAQ Uplisting for Higher Market Exposure and Wide Corporate Benefits to AI Boosted Marketing Company On Track Towards $1 Billion Revenue by 2027
- AAR announces investor conference schedule for May and June 2025
- Congressional Men's Health Caucus Shows Bipartisan Consensus and Focus on Prevention, Mental Health, and Closing the Lifespan Gap
- The Alternative AI Architecture That Creates Certainty and Trust - No More Guesses.